Skip to main content

Table 4 Differences in clinical and serological characteristics of PR3/MPO-ANCA positive antithyroid DIDs

From: Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides

 

Antithyroid drug-induced vasculitides (n = 4)

Antithyroid drug-induced LLD (n = 12)

Age, years (range)

35 ± 6 (20–40)

30 ± 8 (25–52)

Female

3 (75)

12 (100)

Graves' disease

4 (100)

9 (75)

Hashimoto thyroiditis

0

3 (25)

Florid hyperthyroidism

4 (100)

3 (25)

Relapse of hyperthyroidism

2 (50)

4 (33.3)

Antimicrosomal Ab

3 (75)

10 (83.3)

Antithyroid drug therapy, months

21 ± 6

18 ± 7

Months between first complaints and ANCA detection

3 ± 1.5

2 ± 1

Propylthiouracil

2 (50)

10 (83.3)

Methimazole

2 (50)

2 (16.7)

Renal manifestations

2 (50)

1 (8.3)

Lung manifestations

3 (75)

0

Skin manifestations

0

10 (83.3)

PANCA

3 (75)

12 (100)

CANCA

1 (25)

0

MPO-ANCA (U/ml)

65 ± 20

53 ± 15

PR3-ANCA (U/ml)

44

-

ANA

0

8 (66.6)

aCL IgG, IgM

0

9 (75)

Anti-β2 GP I IgG, IgM

0

4 (33.3)

Cryoglobulinemia

0

3 (25)

Low C4 (<0.1 g/l)

0

3 (25)

High CR-P (>10 mg/l)

4 (100)

4 (33.3)

Leucopenia (<3 × l09/l)

0

2 (16.7)

  1. All values represent either numbers of patients (%), or mean ± standard deviation. Ab, antibodies; aCL, anticardiolipin antibodies; ANA, antinuclear antibodies; anti-β2 GP I, anti-beta 2 glycoprotein I; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies; CR-P, C reactive protein; LLD, lupus-like disease; MPO, myeloperoxidase; PR3, proteinase 3; pANCA, perinuclear antineutrophil cytoplasmic antibodies.